Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 3;4(7):e005005.
doi: 10.1136/bmjopen-2014-005005.

Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study

Karlo Mihovilović  1 , Bojana Maksimović  1 , Branislav Kocman  2 , Denis Guštin  3 , Zeljko Vidas  4 , Stela Bulimbašić  5 , Danica Galešić Ljubanović  6 , Mirjana Sabljar Matovinović  1 , Mladen Knotek  7
Affiliations

Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study

Karlo Mihovilović et al. BMJ Open. .

Abstract

Objectives: Chronic transplant dysfunction after kidney transplantation is a major reason of kidney graft loss and is caused by immunological and non-immunological factors. There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate the role of MMF doses on progression of chronic allograft dysfunction and fibrosis and tubular atrophy (IF/TA).

Setting: Retrospective, cohort study.

Participants: Patients with kidney transplant in a tertiary care institution. This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-interleukin 2 antibody induction, MMF, a calcineurin inhibitor±steroids.

Primary outcome measures: An association of average MMF doses over 1 year post-transplant with progression of interstitial fibrosis (Δci), tubular atrophy (Δct) and estimated-creatinine clearance (eCrcl) at 1 year post-transplant was evaluated using univariate and multivariate analyses.

Results: A higher average MMF dose was significantly independently associated with better eCrcl at 1 year post-transplant (b=0.21±0.1, p=0.04). In multiple regression analysis lower Δci (b=-0.2±0.09, p=0.05) and Δct (b=-0.29±0.1, p=0.02) were independently associated with a greater average MMF dose. There was no correlation between average MMF doses and incidence of acute rejection (p=0.68).

Conclusions: A higher average MMF dose over 1 year is associated with better renal function and slower progression of IF/TA, at least partly independent of its immunosuppressive effects.

Keywords: Transplant Medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated-creatinine clearance during first year post-transplant.
Figure 2
Figure 2
Correlation between average mycophenolate mofetil dose and progression of (A) ci score and (B) ct score.
Figure 3
Figure 3
Estimated-creatinine clearance by (A) ci score and (B) ct score.
See this image and copyright information in PMC

References

    1. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580–90 - PubMed
    1. Kuypers DR, Chapman JR, O'Connell PJ, et al. Predictors of renal transplant histology at three months. Transplantation 1999;67:1222–30 - PubMed
    1. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994;57:857–9 - PubMed
    1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326–33 - PubMed
    1. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:860–5 - PubMed

Publication types